AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 93 min read$JNJ

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demo

Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026, showing sustained skin clearance and safety in treating plaque psoriasis. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The drug is approved for adults and adolescents with moderate-to-severe plaque psoriasis.

Original reporting
gurufocus.com
Published Oct 9, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

Positive efficacy and safety data could drive JNJ stock higher and influence dermatology treatment landscape.

02

Market read

First disclosure of pivotal trial data for a major pharma product, likely to affect JNJ valuation and sector sentiment.

03

What to watch

Potential competition from other IL-23 inhibitors and reimbursement uncertainties.

Relevance 7/10Novelty 8/10Timing: today

Background

Press release from Johnson & Johnson announcing Phase 3 ICONIC-LEAD data for ICOTYDE, an oral peptide for plaque psoriasis.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson disclosed two-year Phase 3 data for ICOTYDE showing >70% clear skin at 2 years, a first report of these results.

Expected impact

upward pressure as market prices in the positive trial outcomes.

Evidence & confidence

Phase 3 data are material for a large pharma; JNJ's stock typically reacts positively to successful trial readouts.

Market effects

Sector

May lift sentiment for the broader dermatology and biotech sector.

Regional

Potential modest boost for US healthcare stocks.

Global

Highlights J&J's pipeline strength internationally.

Counterpoint

What could challenge this read

Investors may question long-term market adoption and pricing despite trial success.

Key entities

  • Company
    Johnson & Johnson

    Developer of ICOTYDE, reporting trial results.

  • Drug
    ICOTYDE (icotrokinra)

    First oral peptide targeting IL-23 receptor for plaque psoriasis.

Read at source← All news

StoryJohnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis

Also covered by

2 outlets

Related articles

OCT 9
$JNJMed

Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

rttnews.com2 min
OCT 9
$JNJMed

Johnson & Johnson Reports Positive Two-Year Data on ICOTYDE for

Johnson & Johnson (JNJ) reported positive two-year Phase 3 trial results for ICOTYDE, an oral peptide for plaque psoriasis, with 72% of patients achieving significant skin improvement. The company offers a 1.98% dividend yield, a 55% payout ratio, and a 4.9% 3-year dividend growth rate, but its stock is 32% overvalued relative to its GF Value. JNJ has a GF Score of 83/100, indicating strong financial health and profitability, though insider activity shows significant net selling.

gurufocus.com3 min
OCT 9
$JNJHighAI 9/10

J&J reports ≥72% PASI 90 at Week 112

Johnson & Johnson (JNJ) reported two-year Phase 3 ICONIC-LEAD data for ICOTYDE, showing 72% of patients achieved PASI 90 at Week 112. 70% had clear or almost clear skin, and 78% sustained itch improvement. Safety findings were consistent with the established profile. ICOTYDE is approved in the U.S., Europe, Japan, and China for plaque psoriasis.

grafa.com2 min
OCT 9
$JNJMed

At two years, at least 70% of patients on Johnson & Johnson’s psoriasis pill had clear or almost clear skin.

Johnson & Johnson (JNJ) reported two-year Phase 3 data for ICOTYDE in treating plaque psoriasis, showing 72% of patients achieved 90% skin improvement and 70% had clear/almost clear skin. Retreatment data showed 85% response recovery. No new safety issues were found. ICOTYDE is approved in major markets. Additional studies are ongoing for psoriasis, psoriatic arthritis, and inflammatory bowel diseases.

stocktitan.net3 min